Tag Archives: AMPH

What Did This CEO Just Do with Personal Shares of Amphastar Pharmaceuticals (NASDAQ: AMPH)?

Yesterday, the CEO & Chief Scientific Officer of Amphastar Pharmaceuticals (NASDAQ: AMPH), Jack Zhang, sold shares of AMPH for $6.09M. Following Jack Zhang’s last AMPH Sell transaction on September 15, 2017, the stock climbed by 2.0%. The company has a

Jefferies Remains a Buy on Amphastar Pharmaceuticals

Jefferies analyst David Steinberg reiterated a Buy rating on Amphastar Pharmaceuticals (NASDAQ: AMPH) on October 27 and set a price target of $19. The company’s shares closed on Friday at $18.41. According to TipRanks.com, Steinberg is a 3-star analyst with

Amphastar Pharmaceuticals Gets a Buy Rating from Piper Jaffray

In a report issued on October 20, David Amsellem from Piper Jaffray reiterated a Buy rating on Amphastar Pharmaceuticals (NASDAQ: AMPH), with a price target of $19. The company’s shares closed on Friday at $18.50. According to TipRanks.com, Amsellem is

Amphastar Pharmaceuticals Receives a Buy from Piper Jaffray

In a report issued on September 15, David Amsellem from Piper Jaffray reiterated a Buy rating on Amphastar Pharmaceuticals (NASDAQ: AMPH), with a price target of $19. The company’s shares closed on Friday at $15.73. According to TipRanks.com, Amsellem is

Jefferies Reaffirms Their Buy Rating on Amphastar Pharmaceuticals

Jefferies analyst David Steinberg reiterated a Buy rating on Amphastar Pharmaceuticals (NASDAQ: AMPH) yesterday and set a price target of $19. The company’s shares closed yesterday at $14.89. According to TipRanks.com, Steinberg is a 4-star analyst with an average return

Amphastar Pharmaceuticals Received its Third Buy in a Row

After Jefferies and Wells Fargo assigned a Buy rating to Amphastar Pharmaceuticals in the last month, the company received another Buy, this time from Piper Jaffray. Analyst David Amsellem reiterated a Buy rating on Amphastar Pharmaceuticals (NASDAQ: AMPH) yesterday and